Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kun Run Biotech OK’d to Produce Hepatitis B Drug

publication date: Jun 17, 2010
Kun Run Biotechnology, a China manufacturer of peptide-based and small molecule drugs, received SFDA manufacturing approval for Entecavir, an oral treatment for hepatitis B. Entecavir inhibits reverse transcription, DNA replication and transcription in the viral replication process. Baraclude, which is Bristol-Myers Squibb’s (NYSE: BMS) version of the drug, was approved by the US FDA in 2005 for hepatitis B treatment. More details...

Stock Symbol: (OTCBB: KURU)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital